Addition of pulse corticosteroids to oral prednisone in moderately active ulcerative colitis: a randomized, multicentre, open-label study by GETECCU


Por: Llao, J, Mañosa, M, Martín-Arranz, E, Zabana, Y, Navarro-Llavat, M, Téller, M, Garcia-Planella, E, Busquets, D, Monfort, D, Pineda, JR, Gutiérrez, A, Villoria, A, Menchén, L, Bastida, G, García-Alonso, FJ, Rivero, M, Chaparro, M, de Francisco, R, Merino, O, Rodríguez-Lago, I, Acosta, MBD, Rodríguez-Fortúnez, P, Rodríguez-Jiménez, C, Calafat, M and Domènech, E

Publicada: 1 nov 2025
Resumen:
Background Oral corticosteroids remain the treatment of choice for moderately active ulcerative colitis (UC), achieving clinical remission in 30%-60% of patients.Objective To compare the rates of steroid-free clinical-endoscopic remission at weeks 8 and 54 in patients treated with 3 methyl-prednisolone pulses before oral corticosteroids in moderately active UC versus those only receiving oral corticosteroids.Design Prospective, open, multicentre, randomized, controlled trial. Patients with left/extensive, moderately active UC, naive to immunosuppressants and biological agents, were randomized to receive conventional treatment (CT) with oral prednisone 60 mg/day or the same regimen preceded by an additional daily pulse (AP) of 500 mg of methyl-prednisolone for 3 days. All patients who responded started oral mesalazine and were followed up until month 12 or clinical relapse.Results Seventy-five patients were randomized: 39 were allocated to the CT arm and 36 to the AP arm. Overall, 21 patients achieved clinical-endoscopic remission (28%; 95% confidence interval [CI]: 23%-33%) at both weeks 8 and 54 without needing rescue treatments, being not significantly different between both study groups (23% [95%CI: 14%-32%] CT vs. 33% [95%CI: 21%-45%] AP; P = 0.323). Patients in the AP group had higher rates of clinical response at day 3 and remission at day 7. No significant differences in adverse events were observed. Due to early termination, the study was underpowered, and findings should be interpreted as exploratory.Conclusions The addition of 3 pulses of high-dose corticosteroids to a conventional regimen of oral prednisone does not improve medium and long-term clinical outcomes in moderately active UC.Trial registration codes EudraCT number 2016-001170-15; ClinicalTrials.gov identifier NCT02921555.

Filiaciones:
Llao, J:
 Hosp Badalona Germans Trias & Pujol, Gastroenterol & Hepatol Dept, Ctra Canyet S-N, Badalona 08916, Catalonia, Spain

 Xarxa Assistencial Althaia, Gastoenterol Dept, Manresa, Spain

:
 Hosp Badalona Germans Trias & Pujol, Gastroenterol & Hepatol Dept, Ctra Canyet S-N, Badalona 08916, Catalonia, Spain

 Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain

Martín-Arranz, E:
 Hosp Univ La Paz Idipaz, H Univ La Paz, Gastoenterol Dept, Inst Invest Sanitaria, Madrid, Spain

Zabana, Y:
 Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain

 HU Mutua Terrassa, Gastoenterol Dept, Terrassa, Spain

Navarro-Llavat, M:
 H Moises Broggi, Gastoenterol Dept, Sant Joan Despi, Spain

Téller, M:
 Xarxa Assistencial Althaia, Gastoenterol Dept, Manresa, Spain

Garcia-Planella, E:
 H Santa Creu & St Pau, Gastoenterol Dept, Barcelona, Spain

Busquets, D:
 H Trueta, Gastoenterol Dept, Girona, Spain

Monfort, D:
 Consorci Sanit Terrassa, Gastoenterol Dept, Terrassa, Spain

Pineda, JR:
 H Alvaro Cunqueiro, Gastoenterol Dept, Vigo, Spain

Gutiérrez, A:
 Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain

 HG Univ Dr Balmis & ISABIAL, Gastoenterol Dept, Alicante, Spain

Villoria, A:
 Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain

 Consorci Sanit Parc Tauli, Gastoenterol Dept, Sabadell, Spain

Menchén, L:
 Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain

 Univ Complutense, H Gen Univ, Gastoenterol Dept, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain

Bastida, G:
 H Univ & Politecn La Fe, Gastoenterol Dept, Valencia, Spain

García-Alonso, FJ:
 H Univ Rio Hortega, Gastoenterol Dept, Valladolid, Spain

Rivero, M:
 Hosp Univ Marques Valdecilla, Grp Invest Clin & Traslac Enfermedades Digest, Inst Invest Valdecilla IDIVAL, Santander, Spain

Chaparro, M:
 Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain

 Univ Autonoma Madrid, H Univ La Princesa, Gastoenterol Dept, Inst Invest Sanitaria Princesa, Madrid, Spain

de Francisco, R:
 H Univ Cent Asturias, Gastoenterol Dept, Inst Invest Sanitaria Principado Asturias ISPA, Oviedo, Spain

Merino, O:
 H Cruces, Gastoenterol Dept, Bilbao, Spain

Rodríguez-Lago, I:
 Hosp Univ Galdakao, Gastoenterol Dept, Inst Invest Sanitaria Biobizkaia, Galdakao, Spain

Acosta, MBD:
 Complejo Hosp Santiago, Gastoenterol Dept, Santiago De Compostela, Spain

Rodríguez-Fortúnez, P:
 UICEC H Univ Canarias, San Cristobal De La Lagun, Spain

Rodríguez-Jiménez, C:
 UICEC H Univ Canarias, San Cristobal De La Lagun, Spain

:
 Hosp Badalona Germans Trias & Pujol, Gastroenterol & Hepatol Dept, Ctra Canyet S-N, Badalona 08916, Catalonia, Spain

 Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain

:
 Hosp Badalona Germans Trias & Pujol, Gastroenterol & Hepatol Dept, Ctra Canyet S-N, Badalona 08916, Catalonia, Spain

 Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain

 Univ Autonoma Barcelona, Barcelona, Spain
ISSN: 18739946





JOURNAL OF CROHNS & COLITIS
Editorial
Oxford University Press, GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 19 Número: 11
Páginas:
WOS Id: 001641654900001
ID de PubMed: 41258993

MÉTRICAS